About Aviva Systems Biology
Founded in 2002, Aviva Systems Biology develops antibodies, recombinant proteins and immunoassays for life science research, drug development and diagnostics. The company supports proteome-focused research through a portfolio covering thousands of biological targets and multiple species. Its expertise includes antibody development, protein expression, immunoassay design and reagent characterisation. Aviva’s technologies enable researchers to study protein expression, biomarker biology and disease mechanisms across a wide range of applications. Products support workflows including western blotting, immunohistochemistry, immunocytochemistry, flow cytometry and ELISA-based analysis. Research areas served include neuroscience, cancer biology, immunology, cell biology and translational research.
Aviva Systems Biology offers recombinant monoclonal antibodies, monoclonal antibodies, polyclonal antibodies, ELISA kits, recombinant proteins and western blot reagents. Its Protein on Demand™ platform provides semi-custom recombinant protein production, alongside custom antibody, protein and ELISA development services. The company also provides antibody characterisation, large-scale protein production and ISO 13485-supported manufacturing capabilities for research and diagnostic programmes. Technical resources, pathway information and application guidance help support experimental design and data interpretation.
Europa Biosite’s subsidiaries distribute for Aviva Systems Biology in Austria, Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway, Sweden and Switzerland.